Aptus reports successful treatment with EndoStapling Program in Europe Aptus Endosystems Inc.

‘Its use has a strong potential to decrease the necessity for post-EVAR follow-up considerably.’ Subsequent Aptus EndoStaple Program cases had been performed by: Prof. Eric Verhoeven, M.D., Ph.D. Ralf Kolvenbach, M.D., Ph.D., Chief of Vascular Surgery, Augusta Hospital, Dusseldorf, Germany; and Dr. Gaudencio Espinosa, Director of Vascular Procedure, University of Navarra Medical center, Pamplona, Spain. ‘The EndoStapling System performed wonderfully,’ stated Prof. Verhoeven. ‘In unfriendly anatomy, I was able to staple a proximal cuff to repair a sort I endoleak of an endograft that had tilted.’ ‘Completing our first instances in Europe marks a substantial milestone for Aptus Endosystems,’ commented Jeff Elkins, CEO of Aptus Endosystems, Inc.Product sales in Sports Medicine improved $22.3 million, or 10.6 %, december 31 for the entire year ended, 2010 compared to 2009. Contract manufacturing product sales pursuant to the Company’s supply and distribution agreement with Smith & Nephew increased $13.2 million. Sports Medication revenue for the Americas included the reputation of $6.6 million of product sales from prior periods which were deferred pending resolution of certain contract problems with customers which were resolved in the first quarter of 2010. Excluding the impact from recognition of deferred revenue, Americas Sports Medicine proprietary revenue declined $6.1 million, or 4.2 %.